BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
6/20/2007 - Nad Reviews Advertising For RENAISSANCE HEALTH’S ‘REVATROL’
The National Advertising Division (NAD) of the Council of Better Business Bureaus has recommended that Renaissance Health Publishing modify the format for print and Website advertising for the dietary supplement Revatrol, a “red wine” extract. NAD has recommended also that the company discontinue certain claims for the product. -
6/19/2007 - Schering-Plough, Novartis Participate In NAD Forum
The National Advertising Division (NAD) of the Council of Better Business Bureaus has recommended that Schering-Plough Healthcare Products, Inc., modify certain claims for Lotrimin Ultra, a treatment for athlete’s foot. Television advertising claims for Lotrimin Ultra were challenged by Novartis Consumer Healthcare, Inc., the maker of Lamisil Defense, a competing product. -
6/19/2007 - NAD Refers Advertising From ALCOHOLISM CURE FOUNDATION To FTC
The National Advertising Division (NAD) of the Council of Better Business Bureaus will refer advertising claims published by the Alcoholism Cure Foundation to the Federal Trade Commission for possible law enforcement action. -
6/14/2007 - Masterfoods, Russell Stover Participate In NAD Forum
The National Advertising Division (NAD) of the Council of Better Business Bureaus has determined that advertising for Dove Sugar Free Rich Dark Chocolates with [Raspberry, Mint, Chocolate] Crème, manufactured and sold by Masterfoods USA, does not convey an misleading or inaccurate message to consumers. -
6/14/2007 - Nad Reviews Advertising For Sally Hansen ‘No Chip 10 Day Nail Color’
The National Advertising Division (NAD) of the Council of Better Business Bureaus has determined that Del Laboratories has provided reasonable support for certain advertising claims for “Sally Hansen No Chip 10 Day Nail Color.” However, NAD recommended the company modify the claim “No chipping, no cracking, no fading for 10 days guaranteed.” -
6/14/2007 - NAD Examines Advertising For University Medical’s WrinkleFree At Home Wrinkle Reversal System
The National Advertising Division (NAD) of the Council of Better Business Bureaus has recommended that University Medical Pharmaceuticals Corporation modify certain claims for its WrinkleFree At Home Wrinkle Reversal System to avoid conveying the impression that the topical cream and serum will produce the same results as more invasive options, such as injections. -
5/31/2007 - NAD Examines Advertising From Intelligent Beauty
The National Advertising Division (NAD) of the Council of Better Business Bureaus has recommended that Intelligent Beauty LLC modify or discontinue certain performance and superiority claims for the company’s iQ Cosmetics RestorEyes System. -
5/28/2007 - P&G, Colgate Palmolive Participate In NAD Forum
The National Advertising Division (NAD) of the Council of Better Business Bureaus has determined that Procter & Gamble provided a reasonable basis for some advertising claims made for its Crest Pro-Health toothpaste. -
5/15/2007 - NAD Examines Advertising For Wachovia Bank
The National Advertising Division (NAD) of the Council of Better Business Bureaus has determined that Wachovia Bank provided a reasonable basis for the claim that the bank “is obsessed customer service.” However, NAD recommended the bank modify or discontinue a television commercial that recounts the experiences of customer Joe Carta to avoid conveying the message that Wachovia provides a service that may not be typically available. -
5/10/2007 - NAD Refers Advertising For ‘SunPill’ To FTC
The National Advertising Division (NAD) of the Council of Better Business Bureaus will refer advertising made by Pure Pharmaceuticals, LLC for its Sunpill product to the Federal Trade Commission for possible law enforcement action following the company’s refusal to comply with certain recommendations in an earlier NAD decision.